| Literature DB >> 27911344 |
Lauren Heusinkveld1,2, Mallory Hacker1, Maxim Turchan1, Madelyn Bollig1, Christina Tamargo1, William Fisher1, Lauren McLaughlin3, Adria Martig3, David Charles1.
Abstract
The FDA has approved a multicenter, double-blind, Phase III, pivotal trial testing deep brain stimulation (DBS) in 280 people with very early stage Parkinson's disease (PD; IDE#G050016). In partnership with The Michael J. Fox Foundation for Parkinson's Research, we conducted a survey to investigate motivating factors, barriers, and gender differences among potentially eligible patients for participation in a trial testing DBS in early PD compared to standard medical treatment. The majority of survey respondents (72%) indicated they would consider learning more about participating. Early PD patients are therefore likely to consider enrolling in trials of invasive therapies that may slow symptom progression and help future patients.Entities:
Keywords: Parkinson’s disease; deep brain stimulation; patient preference; surveys
Mesh:
Year: 2017 PMID: 27911344 DOI: 10.3233/JPD-161031
Source DB: PubMed Journal: J Parkinsons Dis ISSN: 1877-7171 Impact factor: 5.568